Final overall survival data for phase III PROSPER trial of Xtandi shows significant improvement in prostate cancer.- Astellas Pharma + Pfizer
Related news and insights
Novartis announced that results of the Phase III VISION study evaluating 177Lu-PSMA-617, a targeted radioligand therapy, plus best standard of care (SOC) demonstrated significant improvement in overall survival (OS) compared to SOC alone, in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
Astellas Pharma Inc. announced that the European Commission (EC) has approved an additional indication for the oral once-daily therapy Xtandi (enzalutamide) for adult men with metastatic hormone-sensitive prostate cancer (mHSPC, also known as metastatic castration-sensitive prostate cancer or mCSPC).
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that regulatory submissions based on the Phase III ACIS study, which evaluated the combination of Erleada (apalutamide) and Zytiga (abiraterone acetate) plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC), will not be pursued.